Search

Lavandula stoechas L. subsp. stoechas has traditionally been used in folk medicine for central nervous system (CNS) disorders. In the present study, the potential neuroactive effect of the aqueous ethanol extract of the aerial parts of L. stoechas was investigated, and phytochemical studies were carried out to identify the compounds that may be responsible for this activity. Five compounds were isolated using various chromatographic methods, and their structures were elucidated as luteolin 7-O- β -D-glucopyranoside, rosmarinic acid, eriodictyol, 1-nonadecene, and ursolic acid by spectroscopic methods. Assessing the brain-derived neurotrophic factor (BDNF) level in SH-SY5Y cells was used as a biological screening tool to evaluate the activity, and the extracts, main fractions, and isolated compounds were generally found to increase BDNF levels. Among the isolated compounds, ursolic acid at a concentration of 5 μM, as well as eriodictyol and ursolic acid at a concentration of 10 μM, resulted in the highest increase in BDNF levels. In addition, the potential neuroprotective effects of the isolated compounds against H 2 O 2 -induced neuronal cell damage were investigated. The compounds were found to possess neuroprotective effects, with significant activity observed for eriodictyol at a concentration of 5 μM (p < 0.05) and for 1-nonadecene at concentrations of 2.5 μM (p < 0.001), 5 μM (p < 0.01), and 10 μM (p < 0.001). Additionally, L. stoechas demonstrated strong antioxidant activity, as evidenced by DPPH, SO, NO radical scavenging activity, CUPRAC, and FRAP methods. In conclusion, our results provide support for the traditional use of L. stoechas in CNS disorders. [Display omitted] • Five compounds were isolated from Lavandula stoechas L. subsp. stoechas. • Eriodictyol and ursolic acid were the compounds that most increased BDNF levels. • Eriodictyol and 1-nonadecene exhibited significant neuroprotective effect. • 1-nonadecene from L. stoechas reported for the first time from L. stoechas L. subsp. stoechas. [ABSTRACT FROM AUTHOR]

Objective: There is limited information about kidney transplant recipients who recovered from the Coronavirus disease 2019. This study is conducted to investigate the safety of transplantation in this patient population. Methods: Nineteen patients with prior coronavirus disease 2019 were included. We present demographics, clinical characteristics, laboratory findings, and immunosuppressive regimen. Graft functions and patient and allograft outcomes were compared to 19 kidney transplant recipients who did not have coronavirus disease 2019. Results: The median age of participants was 38 (interquartile range, 26-51) years. Most of the recipients were men (n = 30, 78.9%). The most common presenting symptoms of kidney transplant recipients with prior coronavirus disease 2019 were fever (36.8%), fatigue (21.1%), dyspnea (15.8%), cough (10.5%), and myalgia (5.3%). Eight patients (42.2%) were hospitalized, while none required intensive care unit admission and mechanical ventilation. The median wait time for transplantation after the initial diagnosis of coronavirus disease 2019 was 82 days (interquartile range, 57-172). Most recipients in both groups received antithymocyte globulin as an induction agent. Standard doses of maintenance immunosuppression consisting of tacrolimus, mycophenolate derivatives, and corticosteroids were administered. During a follow-up duration of 85 (interquartile range, 39-154) and 134 (interquartile range, 56-240) days for patients and controls, respectively, the rate of complications and graft functions were not statistically significant between groups. Graft and patient survival was 100%. Conclusion: Our study results support the safety of kidney transplantation in patients with prior coronavirus disease 2019. Transplant candidates and donors should be carefully screened for coronavirus disease 2019. We suggest continuing the standard doses of induction and maintenance immunosuppression, especially in patients who recovered without pulmonary sequelae. [ABSTRACT FROM AUTHOR]

Roemerine is a naturally occurring aporphine alkaloid. In this study, we screened a conformer library of Food and Drug Administration (FDA)-approved drugs to identify similar drugs that can assist in identifying the biological targets of roemerine. To assess the neuroactivity in vitro, we measured the levels of cell metabolites, Brain-Derived Neurotrophic Factor (BDNF) and serotonin (5-HT) in SH-SY5Y cell line. By means of structure-based virtual screening, we identified five drugs that are similar to roemerine; mirtazapine, atomoxetine, epinastine, diphenhydramine and orphenadrine. GC-MS metabolomics study revealed that roemerine has a high impact on alanine-aspartate-glutamate pathway in cell lysate and cultured medium. Additionally, roemerine increased intercellular 5-HT level and intracellular BDNF protein expression at 10 µM. In conclusion, roemerine — a major alkaloid in antidepressant-like effect possessing plants (P. lacerum and P. syriacum) — has a neuronal activity through increasing BDNF protein expression and affecting serotonergic and glutamatergic systems in SH-SY5Y cell line. [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Society of Cardiology / Türk Kardiyoloji Derneği Arşivi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: In this study we aimed to evaluate the mean platelet volume (MPV) and Plateletcrit (PCT) associated with blood coagulability in patients with severe obstructive sleep apnea syndrome (OSAS). Materials And Methods: The polysomnography recordings of 98 patients admitted to the sleep laboratory before September 2013 were retrospectively evaluated. All cases were grouped according to their AHI value as AHI <5 / h (n = 48) Group A (control) and AHI ≥ 30 / hour and Group B (n = 50). MPV and PCT (plateletcrit) was measured using an automatic blood cell counter. Polysomnographic findings, demographic data and blood parameters were compared. Results: No significant differences were found between A and B groups with respect to PCT (0.218±0.06 vs. 0.212±0.05, p=0.66) and MPV (7.17±0.98 vs. 7.54±1.21fL, p=0.66). In severe OSAS group, MPV and PCT werenot correlated with AHİ (r=0.37, p=0.801 and r=0.61, p=0.624). Conclusion: MPV and PCT levels werenot higher in severe OSAS group compared to the control group. Unlike previous studies, these findings suggest that MPV isnot associated with the severity of OSAS and OSAS does not directly affect the platelet activity. [ABSTRACT FROM AUTHOR]

Context: Bellis perennis L. (Asteraceae) (common daisy) is a herbaceous perennial plant known as a traditional wound herb; it has been used for the treatment of bruises, broken bones, and wounds. Bellis perennis has also been used in the treatment of headache, common cold, stomachache, eye diseases, eczema, skin boils, gastritis, diarrhea, bleeding, rheumatism, inflammation, and infections of the upper respiratory tract in traditional medicine. Objective: Antitumor activities of different fractions of B. perennis flowers at different concentrations were evaluated and through bioassay-guided fractionation and isolation procedures a saponin derivative ( 1) was isolated from the active fraction obtained from the n-butanol extract of flowers of the title plant by column chromatography. Materials and methods: Antitumor activities of different fractions of B. perennis flowers at different concentrations were evaluated using Potato Disc Tumor Induction Bioassay. Structure elucidation of 1 was accomplished by spectroscopic methods [1D- and 2D-NMR, and LC-ESI(APCI)-TOF-MS(MSn)]. Results: The present study showed the antitumor activity of fractions obtained from B. perennis flowers for the first time. The most active fraction showed 99% tumor inhibition at 3000 mg/L. An oleanane-type saponin was isolated through bioassay-guided studies. Discussion and conclusion: Through antitumoral bioassay-guided fractionation and isolation procedures, 1 was isolated from the active fraction of B. perennis. The detailed NMR data of compound 1 is given for the first time. [ABSTRACT FROM AUTHOR]

Copyright of Implant Dentistry is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)